1887

Journal of General Virology header logo

Volume 88, Issue 3

Deletion of a major neutralizing epitope of human papillomavirus type 16 virus-like particles Free

Abstract

Human papillomavirus type 16 (HPV-16) is a major cause of human cancer. Effective prophylactic vaccines are based on type-specific neutralizing antibodies. A major neutralizing epitope has been defined by the monoclonal antibody H16.V5. To investigate the importance of this epitope for overall immunogenicity of HPV-16, HPV-16 virus-like particles devoid of the H16.V5 epitope were engineered by site-directed mutagenesis of ten non-conserved, surface-exposed residues. Removal of the H16.V5-defined epitope had only a marginal effect on antigenic reactivity with antibodies in sera from infected subjects, but affected immunogenicity in experimental immunization of mice, with reduced induction of both antibody responses and CTL responses.

  • Received:
  • Accepted:
  • Published Online:
SGM
Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.82449-0
2007-03-01
2024-04-24
Loading full text...

Full text loading...

/deliver/fulltext/jgv/88/3/792.html?itemId=/content/journal/jgv/10.1099/vir.0.82449-0&mimeType=html&fmt=ahah

References

  1. Andersson-Ellstrom A., Dillner J., Hagmar B., Schiller J., Sapp M., Forssman L., Milsom I. 1996; Comparison of development of serum antibodies to HPV16 and HPV33 and acquisition of cervical HPV DNA among sexually experienced and virginal young girls. A longitudinal cohort study. Sex Transm Dis 23:234–238 [CrossRef]
     [Google Scholar]
  2. Bosch F. X., de Sanjosé S. 2003; Chapter 1: Human papillomavirus and cervical cancer – burden and assessment of causality. J Natl Cancer Inst Monogr 31:3–13
     [Google Scholar]
  3. Bosch F. X., Manos M. M., Muñoz N., Sherman M., Jansen A. M., Peto J., Schiffman M. H., Moreno V., Kurman R., Shah K. V. 1995; Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 87:796–802 [CrossRef]
     [Google Scholar]
  4. Brown D. R., Fife K. H., Wheeler C. M., Koutsky L. A., Lupinacci L. M., Railkar R., Suhr G., Barr E., Dicello A. 2004; Early assessment of the efficacy of a human papillomavirus type 16 L1 virus-like particle vaccine. Vaccine 22:2936–2942 [CrossRef]
     [Google Scholar]
  5. Carter J. J., Wipf G. C., Benki S. F., Christensen N. D., Galloway D. A. 2003; Identification of a human papillomavirus type 16-specific epitope on the C-terminal arm of the major capsid protein L1. J Virol 77:11625–11632 [CrossRef]
     [Google Scholar]
  6. Carter J. J., Wipf G. C., Madeleine M. M., Schwartz S. M., Koutsky L. A., Galloway D. A. 2006; Identification of human papillomavirus type 16 L1 surface loops required for neutralization by human sera. J Virol 80:4664–4672 [CrossRef]
     [Google Scholar]
  7. Chackerian B., Lenz P., Lowy D. R., Schiller J. T. 2002; Determinants of autoantibody induction by conjugated papillomavirus virus-like particles. J Immunol 169:6120–6126 [CrossRef]
     [Google Scholar]
  8. Chen X. S., Garcea R. L., Goldberg I., Casini G., Harrison S. C. 2000; Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16. Mol Cell 5:557–567 [CrossRef]
     [Google Scholar]
  9. Christensen N. D., Hopfl R., DiAngelo S. L., Cladel N. M., Patrick S. D., Welsh P. A., Budgeon L. R., Reed C. A., Kreider J. W. 1994; Assembled baculovirus-expressed human papillomavirus type 11 L1 capsid protein virus-like particles are recognized by neutralizing monoclonal antibodies and induce high titres of neutralizing antibodies. J Gen Virol 75:2271–2276 [CrossRef]
     [Google Scholar]
  10. Christensen N. D., Cladel N. M., Reed C. A., Budgeon L. R., Embers M. E., Skulsky D. M., McClements W. L., Ludmerer S. W., Jansen K. U. 2001; Hybrid papillomavirus L1 molecules assemble into virus-like particles that reconstitute conformational epitopes and induce neutralizing antibodies to distinct HPV types. Virology 291:324–334 [CrossRef]
     [Google Scholar]
  11. Clifford G. M., Smith J. S., Plummer M., Muñoz N., Franceschi S. 2003; Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 88:63–73 [CrossRef]
     [Google Scholar]
  12. Da Silva D. M., Pastrana D. V., Schiller J. T., Kast W. M. 2001; Effect of preexisting neutralizing antibodies on the anti-tumor immune response induced by chimeric human papillomavirus virus-like particle vaccines. Virology 290:350–360 [CrossRef]
     [Google Scholar]
  13. De Bruijn M. L., Greenstone H. L., Vermeulen H., Melief C. J., Lowy D. R., Schiller J. T., Kast W. M. 1998; L1-specific protection from tumor challenge elicited by HPV16 virus-like particles. Virology 250:371–376 [CrossRef]
     [Google Scholar]
  14. de Villiers E. M., Fauquet C., Broker T. R., Bernard H. U., zur Hausen H. 2004; Classification of papillomaviruses. Virology 324:17–27 [CrossRef]
     [Google Scholar]
  15. Dillner L., Heino P., Moreno-Lopez J., Dillner J. 1991; Antigenic and immunogenic epitopes shared by human papillomavirus type 16 and bovine, canine, and avian papillomaviruses. J Virol 65:6862–6871
     [Google Scholar]
  16. Drobni P., Mistry N., McMillan N., Evander M. 2003; Carboxy-fluorescein diacetate, succinimidyl ester labeled papillomavirus virus-like particles fluoresce after internalization and interact with heparan sulfate for binding and entry. Virology 310:163–172 [CrossRef]
     [Google Scholar]
  17. Dupuy C., Buzoni-Gatel D., Touze A., Le Cann P., Bout D., Coursaget P. 1997; Cell mediated immunity induced in mice by HPV 16 L1 virus-like particles. Microb Pathog 22:219–225 [CrossRef]
     [Google Scholar]
  18. Emini E. A., Hughes J. V., Perlow D. S., Boger J. 1985; Induction of hepatitis A virus-neutralizing antibody by a virus-specific synthetic peptide. J Virol 55:836–839
     [Google Scholar]
  19. Ferenczy A., Franco E. 2002; Persistent human papillomavirus infection and cervical neoplasia. Lancet Oncol 3:11–16 [CrossRef]
     [Google Scholar]
  20. Fife K. H., Wheeler C. M., Koutsky L. A., Barr E., Brown D. R., Schiff M. A., Kiviat N. B., Jansen K. U., Barber H. 2004; Dose-ranging studies of the safety and immunogenicity of human papillomavirus Type 11 and Type 16 virus-like particle candidate vaccines in young healthy women. Vaccine 22:2943–2952 [CrossRef]
     [Google Scholar]
  21. Giroglou T., Florin L., Schafer F., Streeck R. E., Sapp M. 2001; Human papillomavirus infection requires cell surface heparan sulfate. J Virol 75:1565–1570 [CrossRef]
     [Google Scholar]
  22. Harper D. M., Franco E. L., Wheeler C., Ferris D. G., Jenkins D., Schuind A., Zahaf T., Innis B., Naud P. 2004; Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364:1757–1765 [CrossRef]
     [Google Scholar]
  23. Hopp T. P., Woods K. R. 1981; Prediction of protein antigenic determinants from amino acid sequences. Proc Natl Acad Sci U S A 78:3824–3828 [CrossRef]
     [Google Scholar]
  24. Jameson B. A., Wolf H. 1988; The antigenic index: a novel algorithm for predicting antigenic determinants. Comput Appl Biosci 4:181–186
     [Google Scholar]
  25. Joyce J. G., Tung J.-S., Przysiecki C. T., Cook J. C., Lehman E. D., Sands J. A., Jansen K. U., Keller P. M. 1999; The L1 major capsid protein of human papillomavirus type 11 recombinant virus-like particles interacts with heparin and cell-surface glycosaminoglycans on human keratinocytes. J Biol Chem 274:5810–5822 [CrossRef]
     [Google Scholar]
  26. Kirnbauer R., Booy F., Cheng N., Lowy D. R., Schiller J. T. 1992; Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci U S A 89:12180–12184 [CrossRef]
     [Google Scholar]
  27. Koutsky L. A., Ault K. A., Wheeler C. M., Brown D. R., Barr E., Alvarez F. B., Chiacchierini L. M., Jansen K. U. 2002; A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 347:1645–1651 [CrossRef]
     [Google Scholar]
  28. Le Cann P., Coursaget P., Iochmann S., Touze A. 1994; Self-assembly of human papillomavirus type 16 capsids by expression of the L1 protein in insect cells. FEMS Microbiol Lett 117:269–274 [CrossRef]
     [Google Scholar]
  29. Liu W. J., Liu X. S., Zhao K. N., Leggatt G. R., Frazer I. H. 2000; Papillomavirus virus-like particles for the delivery of multiple cytotoxic T cell epitopes. Virology 273:374–382 [CrossRef]
     [Google Scholar]
  30. Longworth M. S., Laimins L. A. 2004; Pathogenesis of human papillomaviruses in differentiating epithelia. Microbiol Mol Biol Rev 68:362–372 [CrossRef]
     [Google Scholar]
  31. Modis Y., Trus B. L., Harrison S. C. 2002; Atomic model of the papillomavirus capsid. EMBO J 21:4754–4762 [CrossRef]
     [Google Scholar]
  32. Munger K., Baldwin A., Edwards K. M., Hayakawa H., Nguyen C. L., Owens M., Grace M., Huh K. 2004; Mechanisms of human papillomavirus-induced oncogenesis. J Virol 78:11451–11460 [CrossRef]
     [Google Scholar]
  33. Nieland J. D., Da Silva D. M., Velders M. P., de Visser K. E., Schiller J. T., Muller M., Kast W. M. 1999; Chimeric papillomavirus virus-like particles induce a murine self-antigen-specific protective and therapeutic antitumor immune response. J Cell Biochem 73:145–152 [CrossRef]
     [Google Scholar]
  34. Revaz V., Benyacoub J., Kast W. M., Schiller J. T., De Grandi P., Nardelli-Haefliger D. 2001; Mucosal vaccination with a recombinant Salmonella typhimurium expressing human papillomavirus type 16 (HPV16) L1 virus-like particles (VLPs) or HPV16 VLPs purified from insect cells inhibits the growth of HPV16-expressing tumor cells in mice. Virology 279:354–360 [CrossRef]
     [Google Scholar]
  35. Roden R. B., Armstrong A., Haderer P., Christensen N. D., Hubbert N. L., Lowy D. R., Schiller J. T., Kirnbauer R. 1997; Characterization of a human papillomavirus type 16 variant-dependent neutralizing epitope. J Virol 71:6247–6252
     [Google Scholar]
  36. Roden R. B., Ling M., Wu T.-C. 2004; Vaccination to prevent and treat cervical cancer. Hum Pathol 35:971–982 [CrossRef]
     [Google Scholar]
  37. Rudolf M. P., Nieland J. D., DaSilva D. M., Velders M. P., Muller M., Greenstone H. L., Schiller J. T., Kast W. M. 1999; Induction of HPV16 capsid protein-specific human T cell responses by virus-like particles. Biol Chem 380:335–340
     [Google Scholar]
  38. Ruedl C., Schwarz K., Jegerlehner A., Storni T., Manolova V., Bachmann M. F. 2005; Virus-like particles as carriers for T-cell epitopes: limited inhibition of T-cell priming by carrier-specific antibodies. J Virol 79:717–724 [CrossRef]
     [Google Scholar]
  39. Sadeyen J. R., Tourne S., Shkreli M., Sizaret P. Y., Coursaget P. 2003; Insertion of a foreign sequence on capsid surface loops of human papillomavirus type 16 virus-like particles reduces their capacity to induce neutralizing antibodies and delineates a conformational neutralizing epitope. Virology 309:32–40 [CrossRef]
     [Google Scholar]
  40. Shank-Retzlaff M., Wang F., Morley T., Anderson C., Hamm M., Brown M., Rowland K., Pancari G., Zorman J. 2005; Correlation between mouse potency and in vitro relative potency for human papillomavirus type 16 virus-like particles and Gardasil vaccine samples. Hum Vaccin 1:191–197 [CrossRef]
     [Google Scholar]
  41. Slupetzky K., Shafti-Keramat S., Lenz P., Brandt S., Grassauer A., Sara M., Kirnbauer R. 2001; Chimeric papillomavirus-like particles expressing a foreign epitope on capsid surface loops. J Gen Virol 82:2799–2804
     [Google Scholar]
  42. Touze A., El Mehdaoui S., Sizaret P.-Y., Mougin C., Muñoz N., Coursaget P. 1998; The L1 major capsid protein of human papillomavirus type 16 variants affects yield of virus-like particles produced in an insect cell expression system. J Clin Microbiol 36:2046–2051
     [Google Scholar]
  43. Villa L. L., Ault K. A., Giuliano A. R., Costa R. L., Petta C. A., Andrade R. P., Brown D. R., Ferenczy A., Harper D. M. 2006; Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. . : Vaccine 24:5571–5583 [CrossRef]
     [Google Scholar]
  44. Wakabayashi M. T., Da Silva D. M., Potkul R. K., Kast W. M. 2002; Comparison of human papillomavirus type 16 L1 chimeric virus-like particles versus L1/L2 chimeric virus-like particles in tumor prevention. Intervirology 45:300–307 [CrossRef]
     [Google Scholar]
  45. Wang Z., Christensen N., Schiller J. T., Dillner J. 1997; A monoclonal antibody against intact human papillomavirus type 16 capsids blocks the serological reactivity of most human sera. J Gen Virol 78:2209–2215
     [Google Scholar]
  46. Wang X., Wang Z., Christensen N. D., Dillner J. 2003; Mapping of human serum-reactive epitopes in virus-like particles of human papillomavirus types 16 and 11. Virology 311:213–221 [CrossRef]
     [Google Scholar]
  47. White W. I., Wilson S. D., Palmer-Hill F. J., Woods R. M., Ghim S. J., Hewitt L. A., Goldman D. M., Burke S. J., Jenson A. B. 1999; Characterization of a major neutralizing epitope on human papillomavirus type 16 L1. J Virol 73:4882–4889
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.82449-0
Loading
Deletion of a major neutralizing epitope of human papillomavirus type 16 virus-like particles
J. Gen. Virol. 88, 792 (2007); https://doi.org/10.1099/vir.0.82449-0
/content/journal/jgv/10.1099/vir.0.82449-0
/content/journal/jgv/10.1099/vir.0.82449-0
Loading

Data & Media loading...

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error